Authors
Latest:
Treatment Landscape for Vulvar/Vaginal MelanomaAnnelise Wilhite, MD, explains what current treatment options look like for patients with vulvar/vaginal melanoma.
Latest:
Rusfertide May Reduce Need for Therapeutic Phlebotomy in Polycythemia VeraYelena Ginzburg, MD, discusses a long-term goal of the use of rusfertide in patients with chronic polycythemia vera.
Latest:
Impact of Non-ABL1 Mutations on Outcomes in Chronic Myeloid LeukemiaAkriti Jain, MD, discusses her presentation from the 2024 American Society of Hematology Meeting and Exposition.
Latest:
Lutetium-PSMA-617 and Novel Agents in Prostate CancerOncologists share some final thoughts on lutetium-PSMA-617 and novel agents to look out for in prostate cancer treatment.
Latest:
Belumosudil Shows Sustained Efficacy and Safety for Chronic GVHDStephanie Lee, MD, discusses a study investigating belumosudil for chronic graft-vs-host disease.
Latest:
Final Remarks and Thank-YouTiciana Leal, MD, discusses how emerging targeted therapies for extensive-stage small cell lung cancer (ES-SCLC) are showing promising objective clinical outcomes that may surpass those of second-line treatments such as topotecan and CAV regimens, particularly highlighting the need to evaluate specific compounds based on platinum-sensitive vs platinum-resistant disease profiles and the potential role of TIGIT inhibitors in future treatment lines.
Latest:
Exploring Subgroups of Patients Likely to Refuse HSCT for Myeloma TreatmentChakra Chaulagain, MD, discusses findings from a comprehensive examination of National Cancer Database data from 2004 to 2020 regarding the utilization of autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Latest:
Future Treatments in Ovarian CancerAn expert reviews the ongoing ARIEL4 phase III trial and explains what the future of ovarian cancer treatment looks like.
Latest:
HER2-Mutated NSCLC: Second-Line Treatment Selection and Emerging ApproachesPanelists discuss second-line treatment options and emerging approaches for HER2-mutated non–-small cell lung cancer (NSCLC), highlighting novel therapies and clinical strategies.
Latest:
Study Evaluates Use of Radiation Therapy in Pancreatic CancerMichael Chuong, MD, discusses the study design of a trial evaluating radiation therapy in patients with locally advanced pancreatic cancer.
Latest:
Pluvicto Approval Launches Theranostics in Prostate CancerAshok Muthukrishnan, MD, MS, addresses the recent FDA approval of lutetium 177Lu vipivotide tetraxetan and looks to the potential of radioimmunotheranostics on the horizon.
Latest:
Melanoma Monday: From Early Detection to Cutting-Edge TreatmentsMay 6, 2024, is Melanoma Monday. In this article, Niroshana Anandasabapathy, MD, PhD, explores how advancements in detection and treatment are improving the fight against melanoma.
Latest:
Promising New Regimens for Treating Acute Myeloid LeukemiaAlice S. Mims, MD, MSCR, discusses new regimens for treating patients with acute myeloid leukemia, including anti-CD47 immunotherapy, IDH inhibitors, and menin inhibitors.
Latest:
Beyond the Transplant: Long-Term Outcomes and Quality of Life in allo-HCT PatientsNeel Bhatt, MBBS, MPH, discusses a study exploring long-term quality of life outcomes of patients who underwent stem cell transplantation for aplastic anemia.
Latest:
The Ideal Patient for Biomarker Testing in Anal CarcinomaCathy Eng, MD, FACP, FASCO, discusses the types of patients who should be tested for biomarkers in the anal cancer space.
Latest:
Future Outlooks in the Treatment of CLL/SLLFocusing on the future of CLL/SLL treatment, Mazyar Shadman, MD, MPH, discusses promising therapies in the pipeline.
Latest:
AI-Derived Biomarker Predicts Benefit of Long-Term ADT in Prostate CancerAndrew J. Armstrong, MD, ScM, discusses the methods behind a study that established a digital pathology biomarker for the benefit of androgen deprivation therapy in localized high-risk prostate cancer.
Latest:
Importance of NAPOLI 3 in Pancreatic Cancer for Community OncologistsZev A. Wainberg, MD, discusses the pressing relevance of the outcomes of the NAPOLI 3 trial, which were presented at the 2023 Gastrointestinal Cancers Symposium.
Latest:
Hillmen Analyzes Current and Upcoming Trials of BTK InhibitorsDuring a Targeted Oncology Case-Based Peer Perspectives event, Peter Hillmen, MBChB, PhD, discussed the case of 61-year-old patient with diffuse infiltration by chronic leukocytic leukemia.
Latest:
Recommendations for Treating Patients With TP53-Mutated AML or MDSMelhem Solh, MD, discusses the future for patients with myelodysplastic syndrome and acute myeloid leukemia that harbors a TP53 gene mutation, and gives his own recommendations to community oncologists who are treating patients with this disease.
Latest:
Expanding Allogeneic Stem Cell Transplantation for Relapsed and Refractory Acute Myeloid LeukemiaAllogeneic HCT has shown promise as definitive treatment for patients with relapsed or refractory AML.
Latest:
Improved Communication Needed for Patients Living with Renal Cell CarcinomaA lack of understanding about renal cell carcinoma (RCC), clinical trials, and the diseases psychosocial impact may exist in patients living with the illness and their families.
Latest:
Estradiol and Hormone Therapy Show Similar PSA Response in Prostate CancerProstate-specific antigen responses were similar between transdermal estradiol and hormone therapy combined with androgen receptor inhibitors in prostate cancer.
Latest:
Evolving Strategies in Hematopoietic Stem Cell Transplant ConditioningSergio A. Giralt, MD, discusses what the most commonly used conditioning regimens for patients with myelodysplastic syndrome undergoing transplants are.
Latest:
KEYNOTE-522 Trial: Pembrolizumab Boosts Survival in Early TNBCPeter Schmid, MD, PhD, discusses the background, methods, and design of the phase 3 KEYNOTE-522 trial.
Latest:
Unmet Needs Persist for Patients with MelanomaMaya Dimitrova, MD, discusses areas of further research and unmet needs for patients with melanoma.
Latest:
How Self-Monitoring and Data Sharing Produce Better Patient OutcomesMore than half of all patients do not remember their physicians’ recommendations and treatments unless prompted.
Latest:
CAR T-Cell Therapy Shows Consistent Safety and Pharmacokinetics in NHLScott R. Solomon, MD, discusses the adverse events and pharmacokinetics of lisocabtagene maraleucel in 12 patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who had previously received anti-CD19 therapy.
